Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aclaris Therapeutics, Inc. (ACRS)

9.335   0.055 (0.59%) 06-09 14:42
Open: 9.3 Pre. Close: 9.28
High: 9.37 Low: 9.16
Volume: 135,857 Market Cap: 660(M)

Technical analysis

as of: 2023-06-09 2:13:04 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 11.28     One year: 13.17
Support: Support1: 8.55    Support2: 7.86
Resistance: Resistance1: 9.65    Resistance2: 11.28
Pivot: 8.72
Moving Average: MA(5): 9.34     MA(20): 8.58
MA(100): 10.41     MA(250): 13.68
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 80.9     %D(3): 84.6
RSI: RSI(14): 62.2
52-week: High: 18.95  Low: 5.76
Average Vol(K): 3-Month: 647 (K)  10-Days: 559 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ACRS ] has closed below upper band by 15.5%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.39 - 9.44 9.44 - 9.48
Low: 8.93 - 9 9 - 9.05
Close: 9.18 - 9.28 9.28 - 9.36

Company Description

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Headline News

Tue, 06 Jun 2023
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Simply Wall St

Fri, 02 Jun 2023
Aclaris Therapeutics to Participate in Two June Healthcare Investor ... - InvestorsObserver

Tue, 30 May 2023
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decline in ... - MarketBeat

Tue, 23 May 2023
Peter Kolchinsky-led RA Capital's New Positions Feature CureVac ... - Nasdaq

Mon, 22 May 2023
HighTower Advisors LLC Seizes Opportunity to Lift Stake in Aclaris ... - Best Stocks

Sat, 20 May 2023
Aclaris Therapeutics Emerges as a Strong Contender in the ... - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 71 (M)
Shares Float 56 (M)
% Held by Insiders 2.5 (%)
% Held by Institutions 97.7 (%)
Shares Short 4,650 (K)
Shares Short P.Month 4,980 (K)

Stock Financials

EPS -1.5
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.63
Profit Margin (%) 0
Operating Margin (%) -310.7
Return on Assets (ttm) -26.3
Return on Equity (ttm) -54
Qtrly Rev. Growth 74
Gross Profit (p.s.) -0.85
Sales Per Share 0.43
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -73 (M)
Levered Free Cash Flow -41 (M)

Stock Valuations

PE Ratio -6.25
PEG Ratio -0.1
Price to Book value 3.56
Price to Sales 21.48
Price to Cash Flow -9.08

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.